Resources > Supplements > Life Sciences IP Focus 2012

Life Sciences IP Focus 2012

  • Editorial

  • Interview: Robert Armitage, Eli Lilly

    The American Invents Act could have a big effect on the life sciences industry. Kevin Matha spoke with Robert A Armitage, senior vice president and general counsel at Eli Lilly, about the new legislative package

  • Interview: Looking back on decades of industry change

    Tom Ciotti and Kate Murashige of Morrison & Foerster have been involved with the life sciences industry for almost 50 years. Phillip Bausk spoke with them about the changes they have seen in that time

  • Europe: Patenting plant breeding

    Edward J Farrington of Inspicos considers the role of human intervention when acertaining the limits of patentability in plant breeding

  • Europe: Selection inventions

    Louise Tottie and Anette Romare of Valea outline important aspects of selection inventions relating to lists and ranges, to consider when drafting patent applications

  • Mexico: New practice on medical-use claims

    Agustín Azcatl, Daniel Sánchez and Pedro Herrera of Olivares & Cia explain the impact of rule changes on first medical-use claims

  • US: The America Invents Act

    Ha Kung Wong and John Kirkland of Fitzpatrick Cella Harper & Scinto use three scenarios to examine the impact of the Act and the future of paragraph IV litigation


More from the Managing IP blog


Read this year's INTA Daily News - published daily by Managing IP direct from the the 135th INTA Annual Meeting in Dallas


 
 

 
 


May 2013

Look behind the salaries

A survey of the largest IP practices in the US reveals rising compensation, but only at general-practice firms. And partners are having a hard time everywhere. Alli Pyrah explains who is hiring and what lawyers they need



Most read articles

Poll

Following the US Apple v Samsung trial, do you think juries should play a role in patent cases?







Supplements

Change font size: Switch to default font size Switch to medium font size Switch to large font size
Back to top

The material on this site is for financial institutions, professional investors and their professional advisers. It is for information only. Please read our Terms and Conditions and Privacy Policy before using the site. All material subject to strictly enforced copyright laws. © 2013 Euromoney Institutional Investor PLC. For help please see our FAQ.